At the 12 month follow up, they found:
- Steep K values decreased by 0.7D while controls continued to steepen by 0.6D.
- Visual acuity improved by 5 letters.
- Corneal haze was the most frequent adverse event.
To refresh you, Avedro received FDA approval for corneal cross-linking for both keratoconus (approved April 2016) and corneal ectasia following refractive surgery (approved July 2016). So far, the one year results for both have been positive.